TN2009000257A1 - Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1, m2 et m3. - Google Patents
Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1, m2 et m3.Info
- Publication number
- TN2009000257A1 TN2009000257A1 TNP2009000257A TN2009000257A TN2009000257A1 TN 2009000257 A1 TN2009000257 A1 TN 2009000257A1 TN P2009000257 A TNP2009000257 A TN P2009000257A TN 2009000257 A TN2009000257 A TN 2009000257A TN 2009000257 A1 TN2009000257 A1 TN 2009000257A1
- Authority
- TN
- Tunisia
- Prior art keywords
- azabicyclo
- phenothiazine
- ylmethyl
- medicament
- oct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne l'utilisation du 10-[(3R)-]-azabicyclo[2.2.2.]oct-3-ylméthyl]-10- H phénothiazine ainsi que de ses sels pharmaceutiquement acceptables pour la préparation d'un médicament permettant en particulier de prévenir ou de traiter l'incontinence urinaire et ce par voie locale et/ou par voie orale.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0656002A FR2910814B1 (fr) | 2006-12-28 | 2006-12-28 | Utilisation du 10-°(r3)-1-azabicyclo°2.2.2!oct-3-ylmethyl!-10h- phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1,2,3 |
PCT/EP2007/064553 WO2008080924A1 (fr) | 2006-12-28 | 2007-12-26 | Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylméthyl]-10h-phénothiazine pour la préparation d'un médicament exerçant une inhibition sélective des récepteurs muscariniques m1, m2 et m3 |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2009000257A1 true TN2009000257A1 (fr) | 2010-10-18 |
Family
ID=37951872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2009000257A TN2009000257A1 (fr) | 2006-12-28 | 2009-06-23 | Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1, m2 et m3. |
Country Status (22)
Country | Link |
---|---|
US (1) | US8143245B2 (fr) |
EP (1) | EP2124956A1 (fr) |
JP (1) | JP5564263B2 (fr) |
KR (1) | KR101465277B1 (fr) |
CN (1) | CN101573120B (fr) |
AR (1) | AR064714A1 (fr) |
AU (1) | AU2007341274B2 (fr) |
BR (1) | BRPI0720591A2 (fr) |
CA (1) | CA2674162A1 (fr) |
FR (2) | FR2910814B1 (fr) |
HK (1) | HK1133207A1 (fr) |
IL (1) | IL199557A (fr) |
MA (1) | MA31026B1 (fr) |
MX (1) | MX2009006950A (fr) |
NO (1) | NO20092654L (fr) |
NZ (1) | NZ577915A (fr) |
RU (1) | RU2449794C2 (fr) |
TN (1) | TN2009000257A1 (fr) |
TW (1) | TWI423806B (fr) |
UA (1) | UA98131C2 (fr) |
WO (1) | WO2008080924A1 (fr) |
ZA (1) | ZA200904304B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015133989A (ja) * | 2015-04-28 | 2015-07-27 | 重泉 達志 | 健康食品 |
KR101969263B1 (ko) | 2018-07-16 | 2019-04-15 | 이상호 | 산소 챔버용 산소 공급 장치 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1173445B (it) * | 1984-03-16 | 1987-06-24 | Guidotti & C Spa Labor | Agenti ad attivita' antibroncospastica e composizioni farmaceutiche che li contengono |
IT1251161B (it) * | 1991-08-07 | 1995-05-04 | Derivati ammonio quaternari di (-) e (+)-3-(10 h-fenotiazin-10-ilmetil)-l-azabiciclo (2.2.2.)ottano e composizioni farmaceutiche che li contengono | |
AU6686700A (en) | 1999-08-23 | 2001-03-19 | H. Lundbeck A/S | Treatment of urinary incontinence |
MXPA04006017A (es) * | 2001-12-20 | 2005-06-08 | Femmepharma Inc | Suministro de farmacos por via vaginal. |
-
2006
- 2006-12-28 FR FR0656002A patent/FR2910814B1/fr not_active Expired - Fee Related
-
2007
- 2007-12-13 TW TW096147644A patent/TWI423806B/zh not_active IP Right Cessation
- 2007-12-26 NZ NZ577915A patent/NZ577915A/en not_active IP Right Cessation
- 2007-12-26 JP JP2009543465A patent/JP5564263B2/ja not_active Expired - Fee Related
- 2007-12-26 WO PCT/EP2007/064553 patent/WO2008080924A1/fr active Application Filing
- 2007-12-26 BR BRPI0720591-0A patent/BRPI0720591A2/pt not_active IP Right Cessation
- 2007-12-26 UA UAA200907928A patent/UA98131C2/ru unknown
- 2007-12-26 MX MX2009006950A patent/MX2009006950A/es active IP Right Grant
- 2007-12-26 CA CA002674162A patent/CA2674162A1/fr not_active Abandoned
- 2007-12-26 KR KR1020097013047A patent/KR101465277B1/ko not_active IP Right Cessation
- 2007-12-26 EP EP07858150A patent/EP2124956A1/fr not_active Withdrawn
- 2007-12-26 AU AU2007341274A patent/AU2007341274B2/en not_active Ceased
- 2007-12-26 RU RU2009128326/15A patent/RU2449794C2/ru not_active IP Right Cessation
- 2007-12-26 US US12/521,067 patent/US8143245B2/en not_active Expired - Fee Related
- 2007-12-26 CN CN2007800467680A patent/CN101573120B/zh not_active Expired - Fee Related
- 2007-12-28 AR ARP070105989A patent/AR064714A1/es unknown
-
2009
- 2009-01-01 ZA ZA200904304A patent/ZA200904304B/xx unknown
- 2009-06-23 TN TNP2009000257A patent/TN2009000257A1/fr unknown
- 2009-06-25 IL IL199557A patent/IL199557A/en not_active IP Right Cessation
- 2009-06-26 MA MA32046A patent/MA31026B1/fr unknown
- 2009-07-13 NO NO20092654A patent/NO20092654L/no not_active Application Discontinuation
-
2010
- 2010-01-27 HK HK10100843.7A patent/HK1133207A1/xx not_active IP Right Cessation
-
2011
- 2011-03-17 FR FR1152199A patent/FR2953721A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
HK1133207A1 (fr) | 2010-03-19 |
RU2009128326A (ru) | 2011-02-10 |
EP2124956A1 (fr) | 2009-12-02 |
CN101573120A (zh) | 2009-11-04 |
JP2010514730A (ja) | 2010-05-06 |
US20100063276A1 (en) | 2010-03-11 |
TWI423806B (zh) | 2014-01-21 |
MX2009006950A (es) | 2009-07-14 |
IL199557A (en) | 2014-09-30 |
AR064714A1 (es) | 2009-04-22 |
FR2910814B1 (fr) | 2011-06-17 |
KR101465277B1 (ko) | 2014-11-27 |
JP5564263B2 (ja) | 2014-07-30 |
RU2449794C2 (ru) | 2012-05-10 |
AU2007341274B2 (en) | 2012-09-20 |
MA31026B1 (fr) | 2009-12-01 |
BRPI0720591A2 (pt) | 2014-02-25 |
ZA200904304B (en) | 2010-06-30 |
WO2008080924A1 (fr) | 2008-07-10 |
FR2910814A1 (fr) | 2008-07-04 |
NZ577915A (en) | 2011-12-22 |
CA2674162A1 (fr) | 2008-07-10 |
TW200833331A (en) | 2008-08-16 |
CN101573120B (zh) | 2011-11-23 |
UA98131C2 (ru) | 2012-04-25 |
US8143245B2 (en) | 2012-03-27 |
KR20090103887A (ko) | 2009-10-01 |
FR2953721A1 (fr) | 2011-06-17 |
NO20092654L (no) | 2009-09-28 |
AU2007341274A1 (en) | 2008-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN08313A1 (fr) | Des formes pharmaceutiques resistantes a la modification | |
MA30412B1 (fr) | Composés Pharmaceutiques | |
TW200716139A (en) | Methods and compositions for managing psychotic disorders | |
LU92323I2 (fr) | La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate | |
MA30952B1 (fr) | Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt | |
MA37711A1 (fr) | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton | |
MA32049B1 (fr) | Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp | |
MA34207B1 (fr) | Inhibiteurs de la pi3 kinase et/ou du mtor | |
MA30725B1 (fr) | Administration d'inhibiteurs de la dipeptidyl peptidase | |
MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
MA32070B1 (fr) | Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés | |
MX2012004848A (es) | Compuestos heterociclicos triciclicos. | |
MA29799B1 (fr) | Administration d'inhibiteurs de dipeptidyl peptidase | |
MA30765B1 (fr) | Derives innovants du thiophene | |
MA29795B1 (fr) | Inhibiteurs de la dipeptidyl peptidase permetttant de traiter le diabete | |
WO2005020929A3 (fr) | Formes posologiques a liberation prolongee de ziprasidone | |
MA30988B1 (fr) | Composes destines a inhiber la progression mitotique | |
MA30781B1 (fr) | Inhibiteur de kinase | |
WO2007084560A8 (fr) | INHIBITEURS DE TNFα, DE PDE4 ET DE B-RAF, COMPOSITIONS COMPRENANT CES INHIBITEURS ET MÉTHODES D'UTILISATION ASSOCIÉES | |
MA31008B1 (fr) | Polymorphes d'un antagoniste du recepteur mglur5 | |
WO2007126362A8 (fr) | E ex as een es a s e y s u o y o rea as o ows : composes agonistes des recepteurs muscariniques qui peuvent etre efficaces pour traiter la douleur, la maladie d'alzheimer et/ou la schizophrenie | |
WO2008007211A8 (fr) | Composés de carboxyamide bicycliques à n-bicycloalkyle substitué | |
BRPI0506970A (pt) | derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior | |
TW200733976A (en) | Method for the treatment of cognitive dysfunction | |
MY164900A (en) | Use of an alpha-adrenoceptor antagonist in combination with a muscarinic antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms associated with benign prostatic hyperplasia |